According to GlobalData’s medical device pipeline database, 285 Bacteriology devices are in various stages of development globally. GlobalData’s report Bacteriology provides an overview of the segment’s pipeline landscape and offers detailed analysis of its products. Buy the report here.
Of these devices, 60 are in active development, while the remaining 225 are in an inactive stage of development. There are 42 products in the early stages of development, and the remaining 18 are in the late stages of development.
Reagents, and test kits to detect the pathogenicity of bacteria such as chlamydia, gonococci, syphilis, helicobacter pylori, salmonella and so on.
Innovations in the medical devices sector are linked to the development of new approaches, processes, or technologies for treating, diagnosing, and managing disease in response to demand from healthcare for better patient outcomes and reduce healthcare costs.
Based on an analysis of GlobalData’s Medical Intelligence Center pipeline product database, these actively developed Bacteriology pipeline devices are all expected to be approved within the next ten years.
Currently, private organizations, public entities and institutions are working on the development of Bacteriology devices. Overall, most of these Bacteriology pipeline devices are being developed by private entities.
Key players involved in the active development of Bacteriology include Adaltis, Cepheid, Seegene, Genome Diagnostics, Daan Gene, ProCelo, Roche Diagnostics International, MicroPhage, DiaSorin and L2 Diagnostics.
For a complete picture of the developmental pipeline for Bacteriology devices, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.